Bank of America has increased its price target for Catalyst Pharmaceuticals (CPRX, Financial) to $34, up from the previous target of $33, while maintaining a Buy rating on the stock. This adjustment comes as part of the firm's assessment of first-quarter earnings projections for its commercial-stage biopharmaceutical sector coverage.
Bank of America notes that the first quarter often presents challenges for this sector due to seasonal factors, with many companies receiving leeway in anticipation of stronger growth and results in the latter half of the year. The firm also suggests that the immediate impact of first-quarter results may be overshadowed by broader macroeconomic issues, such as concerns related to pharmaceutical tariffs.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Catalyst Pharmaceuticals Inc (CPRX, Financial) is $33.88 with a high estimate of $40.00 and a low estimate of $31.00. The average target implies an upside of 51.23% from the current price of $22.40. More detailed estimate data can be found on the Catalyst Pharmaceuticals Inc (CPRX) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Catalyst Pharmaceuticals Inc's (CPRX, Financial) average brokerage recommendation is currently 1.4, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Catalyst Pharmaceuticals Inc (CPRX, Financial) in one year is $25.54, suggesting a upside of 14.02% from the current price of $22.4. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Catalyst Pharmaceuticals Inc (CPRX) Summary page.
